Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refin

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $480.5, denoting a

Boston Common Asset Management LLC grew its position in Vertex Pharmaceuticals Incorporated (NASDAQ:

Broderick Brian C grew its position in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 8.5% in

Vertex Pharmaceuticals' latest acquisition grants it access to products with $5 billion peak annual

Assetmark Inc. lowered its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wi

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 7.55% on a

Atumelnant is a promising treatment for congenital adrenal hyperplasia that could be a key part of V

Vertex Pharmaceuticals (VRTX) reached $480.25 at the closing of the latest trading day, reflecting a

Vertex is buying Crinetics Pharmaceuticals for $10 billion. The acquisition could add up to $5 billi

UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the

Truist Securities analyst Danielle Brill maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Bu

Vertex Pharmaceuticals NASDAQ: VRTX said it has entered into a definitive agreement to acquire Crine

Vertex Pharmaceuticals is making clinical and regulatory progress with some promising candidates. Th

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatments, and this has translated i

Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this we

CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.

On CNBC's “Halftime Report Final Trades,” Bryn Talkington, managing partner of Requisite Capital Man

The Halftime Report Final Trades featured stock picks from Bryn Talkington, Jim Lebenthal, Liz Young

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,

Vertex Pharmaceuticals NASDAQ: VRTX recently announced its plans to acquire Crinetics Pharmaceutical

Crinetics' Palsonify was FDA-approved late last year. The company's atumelnant is currently in late

Vertex agreed to buy Crinetics for $85 per share in cash, about $10 billion in equity value. The dea

Vertex Pharmaceuticals (VRTX) closed at $522.25 in the latest trading session, marking a -1.39% move

RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperfo

Vertex to acquire Crinetics for $10 billion, adding approved acromegaly drug Palsonify and late-stag

Baird analyst Brian Skorney maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Underperform an

Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) rose in pre-market trading after being acquired by Vert

Crinetics Pharmaceuticals shares are trading higher in Monday's after-hours session after the co

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX),

Vertex Pharmaceuticals today announced that it has signed a Letter of Intent (LOI) with the pan-Cana

FDA expands Vertex Casgevy label to patients aged 2 and older, making about 5,500 more U.S. children

- First and only approved genetic therapy to treat children as young as 2 years for both severe sick

https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-young-children-s

Jim Lebenthal recommends Vertex Pharmaceuticals in the healthcare sector. Jenny Van Leeuwen picks Ve

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 8.53% on a

U.S. stocks sank Monday as an Iranian drone attack on a UAE petroleum site sent Brent above $114, go

The Fear & Greed Index measures market sentiment based on fear and greed levels, showing little

Focus on earnings reports from Tyson Foods, Williams Companies, Skycorp Solar, Vertex Pharmaceutical

U.S. stocks rose broadly on Tuesday as crude oil plunges over 10% on Trump's Iran end-of-war sig

CRISPR Therapeutics fell Tuesday after unveiling a $350 million convertible notes offering, overshad

Dow Jones index up 200 points on Tuesday, NIO Inc. gained following better-than-expected financial r

After Thursday's broad-based tech selloff, Wall Street staged a rebound as a softer-than-expecte

Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as s

Wall Street opened the week on a mixed note on Monday.

Large-cap laggards slid on weak results/guidance, cuts and capital moves—led by The Trade Desk, Fort